Published in Urol Res on January 01, 1991
Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood (2005) 1.42
Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy (2009) 1.19
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19
Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL. J Leukoc Biol (2012) 1.06
Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol (2006) 1.03
Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol (2007) 0.92
Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol (2010) 0.92
Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol (2010) 0.87
Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infect Immun (2006) 0.87
Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells. Clin Exp Immunol (2007) 0.86
BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis. Cancer Cell Int (2010) 0.86
Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. Oncoimmunology (2012) 0.85
Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol (2011) 0.84
1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer. Oncotarget (2013) 0.84
Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial. Clin Cancer Res (2014) 0.82
Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients. Oncoimmunology (2012) 0.77
Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studies. BBA Clin (2015) 0.77
Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases. Exp Biol Med (Maywood) (2016) 0.75
Immune Cells in Cancer Therapy and Drug Delivery. Mediators Inflamm (2016) 0.75
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67
The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab Anim (1981) 2.90
Absence of intestinal mast cell response in congenitally athymic mice during Trichinella spiralis infection. Nature (1976) 2.70
Serodiagnosis of Trichinella spiralis infections in pigs by enzyme-linked immunosorbent assays. Bull World Health Organ (1974) 2.59
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res (1992) 2.55
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res (1994) 2.34
Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene. Mol Biol Rep (1986) 2.16
Automated prostate volume determination with ultrasonographic imaging. J Urol (1995) 2.13
Reliability of the enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of Trichinella spiralis infections in conventionally raised pigs. J Immunol Methods (1976) 2.09
Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res (1993) 2.09
Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res (1992) 1.98
Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang (2002) 1.80
Direct measurement of microplates and its application to enzyme-linked immunosorbent assay. J Clin Microbiol (1976) 1.68
Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol (1996) 1.64
fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. J Clin Invest (1987) 1.63
A practical clinical method for contour determination in ultrasonographic prostate images. Ultrasound Med Biol (1994) 1.60
Selective detrusor activation by electrical sacral nerve root stimulation in spinal cord injury. J Urol (1997) 1.58
Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer (1995) 1.58
TNM classification of genitourinary tumours 1987--position of the EORTC Genitourinary Group. Br J Urol (1988) 1.55
Letter: Application of ELISA--enzyme linked immunosorbent assay--in the sero-diagnosis of amoebiasis. Trans R Soc Trop Med Hyg (1975) 1.44
Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res (1996) 1.41
Salmonella pathogenesis in germ-free mice. A bacteriological and histological study. Br J Exp Pathol (1971) 1.41
Quality-of-life assessment in patients after laser prostatectomy. Br J Urol (1997) 1.41
Urinary tract infections following laser prostatectomy: is there a need for antibiotic prophylaxis? Br J Urol (1996) 1.38
Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group. Eur J Cancer (1994) 1.38
Comparison of different computer models of the neural control system of the lower urinary tract. Neurourol Urodyn (2000) 1.37
Intestinal phase of Trichinella spiralis in congenitally athymic (nude) mice. J Parasitol (1974) 1.37
Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate (1988) 1.35
Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol (1997) 1.35
The effects of treatment of urinary incontinence in general practice. Fam Pract (1992) 1.32
Application of immunofluorescence and immunoenzyme methods in the serodiagnosis of Trichinella spiralis infection. Ann N Y Acad Sci (1975) 1.31
Comparison of three methods for the detection of Trichinella spiralis infections in pigs by five European laboratories. Bull World Health Organ (1974) 1.30
Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res (1993) 1.29
Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate (1998) 1.27
Trichinella spiralis infection in congenitally athymic (nude) mice. Parasitological, serological and haematological studies with observations on intestinal pathology. Immunology (1977) 1.25
Evaluation of the enzyme-linked immunosorbent assay (ELISA) and other serological tests for the diagnosis of toxoplasmosis. Bull World Health Organ (1980) 1.23
Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy (1985) 1.23
Air pollution is associated with increased level of exhaled nitric oxide in nonsmoking healthy subjects. Arch Environ Health (1999) 1.23
Epidemiology of proctocolitis in the region of Leiden, The Netherlands. A population study from 1979 to 1983. Scand J Gastroenterol (1987) 1.23
Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23
Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol (1999) 1.22
Controlled trial of pelvic floor exercises in the treatment of urinary stress incontinence in general practice. Br J Gen Pract (1991) 1.22
Comparison of four methods for early detection of experimental Trichinella spiralis infections in pigs. Vet Parasitol (1981) 1.21
Association between exhaled nitric oxide, ambient air pollution and respiratory health in school children. Int Arch Occup Environ Health (2002) 1.20
The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. J Urol (1996) 1.19
Molecular analysis of multifocal prostate cancer lesions. J Pathol (1999) 1.19
Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res (1999) 1.19
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol (1993) 1.18
Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res (1991) 1.18
Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer (1997) 1.17
Epidemiology of Crohn's disease in Regio Leiden, The Netherlands. A population study from 1979 to 1983. Gastroenterology (1987) 1.17
Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother (1991) 1.16
Some characteristics of a new multiple-channel photometer for through-the-plate reading of microplates to be used in enzyme-linked immunosorbent assay. J Clin Microbiol (1980) 1.16
Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother (1992) 1.15
The athymic nude rat. III. Natural cell-mediated cytotoxicity. Clin Immunol Immunopathol (1980) 1.15
High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate (1999) 1.13
Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol (1993) 1.12
Value of the patient's case history in diagnosing urinary incontinence in general practice. Br J Urol (1991) 1.12
Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol (1995) 1.11
Treatment of mid- and lower ureteric calculi: extracorporeal shock-wave lithotripsy vs laser ureteroscopy. A comparison of costs, morbidity and effectiveness. Br J Urol (1998) 1.11
Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. Eur J Immunol (1995) 1.11
Comparison of three methods for detection of prolonged experimental trichinellosis in pigs. Vet Parasitol (1984) 1.09
Results of the treatment of neurogenic bladder dysfunction in spinal cord injury by sacral posterior root rhizotomy and anterior sacral root stimulation. J Urol (1996) 1.08
In vivo adherence and colonization of Vibrio cholerae strains that differ in hemagglutinating activity and motility. Infect Immun (1987) 1.08
Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol (2001) 1.08
Influence of high-intensity focused ultrasound on the development of metastases. Eur Urol (1997) 1.07
Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology (1996) 1.07
Mechanization of the enzyme-linked immunosorbent assay (ELISA) for large scale screening of sera. J Immunol Methods (1977) 1.07
Compensation for decreased expression of B7 molecules on Leishmania infantum-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production. Infect Immun (1999) 1.07
A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Br J Cancer (1996) 1.07
Exhaled nitric oxide: a novel biomarker of adverse respiratory health effects in epidemiological studies. Arch Environ Health (2000) 1.06
Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother Pharmacol (1992) 1.05
Grading in superficial bladder cancer. (1). Morphological criteria. Br J Urol (1988) 1.04
Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. J Pathol (1997) 1.04
Reliability of the International Prostate Symptom Score in the assessment of patients with lower urinary tract symptoms and/or benign prostatic hyperplasia. J Urol (1996) 1.02
Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview. Urol Int (1990) 1.02
Personality variables involved in chronic prostatitis. Urology (1993) 1.01
Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res (1987) 1.01